Darbepoetin alfa is a medicine used to treat anemia, which is a low red blood cell count. It helps your body make more red blood cells. It's often used for people who have trouble making red blood cells on their own, such as those with kidney disease.
Every report comes from a Lived member, sent anonymously.
Have you tried Aranesp (Darbepoetin Alfa) for Anemia?
Darbepoetin alfa, sold under the brand name Aranesp, is a prescription injection that helps the body make red blood cells. It treats anemia, a shortage of red blood cells or of hemoglobin (the protein in red blood cells that carries oxygen), in two situations. The first is anemia caused by chronic kidney disease (CKD), in adults and children, whether or not they are on dialysis. The second is anemia caused by chemotherapy that suppresses the bone marrow, in people with cancer (other than myeloid cancers, a group of blood cancers) who have at least two more months of chemotherapy planned. The goal of treatment is narrow: to raise hemoglobin enough to reduce or avoid red blood cell transfusions. Darbepoetin has not been shown to improve quality of life, fatigue or general well-being. Because it takes weeks to work, it cannot replace a transfusion when anemia needs correcting quickly. In cancer care it is not used when the chemotherapy is aimed at a cure, when a person is receiving only hormone therapy, biologic drugs or radiation, or when transfusions can manage the anemia. Darbepoetin belongs to a group of medicines called erythropoiesis-stimulating agents, or ESAs (erythropoiesis is the making of red blood cells). Epoetin alfa, sold as Epogen, Procrit and Retacrit, is a closely related ESA that is usually given more often.
Healthy kidneys make a hormone called erythropoietin, which signals the bone marrow to produce red blood cells. Damaged kidneys make less of it, so fewer red cells are made. Chemotherapy causes anemia differently, by suppressing the bone marrow itself. Darbepoetin is a lab-made protein that sends the same signal as erythropoietin, prompting the marrow to produce more red blood cells. What sets it apart is how long it lasts. Extra sugar chains on the protein slow its removal from the body, so it stays active about three times longer than epoetin alfa when given into a vein. That is why it can be given weekly, every two weeks or, for some people, every four weeks, rather than several times a week. The marrow also needs raw materials to respond, and iron is the main one. Most people with CKD need extra iron at some point during ESA treatment. Other causes of anemia, such as low vitamin B12 or folate, bleeding, or chronic inflammation, are looked for and treated first, because they can keep darbepoetin from working.
Darbepoetin is given as an injection under the skin or into a vein, from single-use vials or prefilled syringes. People on hemodialysis usually receive it into a vein through the dialysis line during their sessions; during chemotherapy it is given under the skin. Others get it at a clinic, or are trained to inject it at home. The dose is usually based on body weight (during chemotherapy it may be a fixed dose) and adjusted by hemoglobin results. Typical schedules are weekly or every two weeks for people on dialysis, every four weeks for many people with CKD who are not on dialysis, and weekly or every three weeks during chemotherapy. Hemoglobin is measured in grams per deciliter (g/dL). In adults with CKD, treatment usually starts only when hemoglobin falls below 10 g/dL. For people on dialysis, the dose is reduced or paused as hemoglobin approaches 11 g/dL; for people not on dialysis, once it goes above 10. These targets are deliberately below the levels of healthy adults, because aiming higher increases serious risks. The care team checks hemoglobin at least weekly after starting or changing the dose, then at least monthly once it is stable. The team adjusts the dose gradually and lowers it if hemoglobin rises quickly. Iron levels are checked before and during treatment. For home injections, keep the medicine in the refrigerator in its carton to protect it from light, and do not freeze or shake it. Use each syringe or vial only once. The needle cover on the prefilled syringe contains latex, which matters for anyone with a latex allergy. If a dose is missed, or too much is given, call the care team for instructions rather than adjusting the next dose on your own.
In studies of people with CKD, the most common side effects were high blood pressure (in about 3 in 10 people), shortness of breath, swelling of the legs or feet, cough, and drops in blood pressure during dialysis. Chest pain from reduced blood flow to the heart (angina), fluid buildup, rash, and clots or other problems in a dialysis access (the fistula, graft or catheter that connects to the dialysis machine) also occurred. In people with cancer, abdominal pain, swelling and blood clots were reported. Children commonly have pain at the injection site. Blood pressure can rise or become harder to control even in people who never had high blood pressure, so it is checked often and blood pressure medicines may be added or adjusted. Following the prescribed blood pressure treatment and diet matters while taking darbepoetin. The most serious dangers of darbepoetin are the clots, strokes and heart problems described under Interactions & Warnings. Call 911 for signs of a stroke (sudden weakness or numbness on one side, trouble speaking or sudden trouble seeing), chest pain, sudden or severe trouble breathing, fainting, a cold, pale arm or leg, or a serious allergic reaction such as swelling around the mouth or eyes or wheezing. A seizure also needs emergency care. Call the care team promptly for pain or swelling in a leg, which can signal a clot, a dialysis access that stops working, or a rash with blisters or peeling skin. After a serious allergic or skin reaction, do not take another dose unless the care team says to. Rarely, the body makes antibodies that block both darbepoetin and its own erythropoietin, causing severe anemia (a condition called pure red cell aplasia). Unusual tiredness, lack of energy or dizziness during treatment should be reported to the care team.
Darbepoetin carries the FDA's most serious warning, a boxed warning, shared with other ESAs. In people with CKD, studies that aimed for hemoglobin levels near those of healthy adults (13 to 14 g/dL) found more deaths, heart attacks, strokes, heart failure and blood clots, including clots in dialysis access, than lower targets did, with no added benefit. In one large trial of people with CKD and type 2 diabetes not on dialysis, darbepoetin aimed at 13 g/dL roughly doubled the risk of stroke compared with placebo, and the risk was especially high in people who had already had a stroke. No hemoglobin target or dose has been shown to avoid these risks, so the lowest dose that reduces the need for transfusions is used. People with heart disease, a past stroke or seizures need particular caution. In people with cancer, ESAs shortened survival or made tumors more likely to grow or return in studies of breast, non-small cell lung, head and neck, cervical and lymphoid cancers (such as lymphoma). This is why darbepoetin is limited to anemia caused by chemotherapy, is not used when the treatment aims at cure, and is stopped when the chemotherapy course ends. Anyone with cancer should discuss these risks with their oncologist before starting. Darbepoetin is not used in people with uncontrolled high blood pressure, people who developed pure red cell aplasia after any ESA, or people who had a serious allergic reaction to it. It is not approved to reduce transfusions around surgery, and ESAs have raised clot risk in surgical patients, so anyone taking it who plans surgery should ask whether a blood thinner is needed. The label lists no specific drug interactions, but the care team should still know about all medicines and supplements, including iron. There is too little information to know whether darbepoetin harms a pregnancy; animal studies showed early pregnancy loss at doses close to the usual starting doses. It is also unknown whether it passes into breast milk. Anyone pregnant, planning pregnancy or breastfeeding should weigh the benefits and risks with the prescriber.
Hemoglobin rises gradually over weeks rather than days, and regular blood tests show whether the medicine is working. In CKD, if hemoglobin has not risen by more than 1 g/dL after four weeks, the dose may be increased. If there is still no adequate response after about 12 weeks of dose increases, higher doses are unlikely to help and may add risk. The team then looks for other causes, such as iron deficiency, infection or blood loss, and may stop the medicine. During chemotherapy, darbepoetin is stopped if there is no response, or transfusions are still needed, after eight weeks, and it is always stopped once the chemotherapy course is finished. For people with CKD, treatment is often long-term, alongside regular checks of hemoglobin, iron and blood pressure. Hemoglobin naturally moves up and down, and a single high or low reading may not call for a dose change. Because the aim is fewer transfusions rather than normal blood counts, some tiredness from anemia may continue even when treatment is working as intended.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Aranesp (Darbepoetin Alfa), what you've noticed, or ask the community a question.